33 results
DEF 14A
LYRA
Lyra Therapeutics Inc
14 Apr 21
Definitive proxy
8:22am
voluntarily filed for Chapter 7 bankruptcy in July 2014. Before that, Ms. Merrifield spent 18 years at Genzyme Corporation, serving in several leadership … Therapeutics, Inc., a therapeutics company. Prior to that, he held research and development leadership positions at Hyalex Orthopaedics, Inc., a medical
PRE 14A
LYRA
Lyra Therapeutics Inc
19 Apr 24
Preliminary proxy
4:20pm
Corporation, serving in several leadership roles, including President of Genzyme Biosurgery, President of Genzyme Genetics and Senior Vice President … prior leadership roles as SVP & Worldwide Medical Head of Immunology at Bristol Myers Squibb (BMS) from March to November 2020, Head of R&D China
8-K
EX-99.1
irsrjq 9a75nv
9 Aug 22
Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
8:37am
8-K
EX-99.1
wqz6ta4
5 Aug 20
Lyra Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
4:05pm
8-K
EX-99.1
hfhahthr
9 Mar 21
Lyra Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results, Provides Corporate Update
4:10pm
10-K
m9utd3 3in
9 Mar 21
Annual report
4:26pm
S-1
nda1qp1
6 Mar 20
IPO registration
12:00am
424B4
s998t5rv
1 May 20
Prospectus supplement with pricing info
4:56pm
DRS
oarx xbt2
8 Nov 19
Draft registration statement
12:00am
S-1/A
0zkr8zzw28t fernc8y
27 Apr 20
IPO registration (amended)
8:32am
DRS/A
zfiaizaa
19 Dec 19
Draft registration statement (amended)
12:00am